Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 12/20 | 0.64 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.62 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.62 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Emakalim SCHEMBL9142302 | 1.00 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Emakalim SCHEMBL7273953 | 1.00 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Emakalim SCHEMBL4258884 | 1.00 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Emakalim SCHEMBL6375795 | 1.00 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL8084996 | 0.91 | ABCC9 (0.53) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL7267817 | 0.87 | ABCC9 (0.52) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL7274507 | 0.87 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Emakalim SCHEMBL5047102 | 0.87 | ABCC9 (0.51) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL8084602 | 0.86 | ABCC9 (0.51) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL9314816 | 0.86 | ABCC9 (0.59) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 662 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076961-A1 | COMBINATION TREATMENTS | Celex Oncology Innovations Limited (GB) | 2026-03-19 | — | — | US | claimed |
| WO-2025078664-A1 | TREATMENT OF METASTATIC OR INVASIVE BRAIN CANCER | Celex Oncology Innovations Limited (GB) | 2025-04-17 | — | — | WO | claimed |
| US-20220347172-A1 | COMBINATION TREATMENTS | Celex Oncology Innovations Limited (GB) | 2022-11-03 | — | — | US | claimed |
| EP-4048274-A1 | COMBINATION TREATMENTS FOR CANCER | Celex Oncology Innovations Limited (GB) | 2022-08-31 | — | — | EP | claimed |
| WO-2021078987-A1 | COMBINATION TREATMENTS FOR CANCER | Celex Oncology Innovations Limited (GB) | 2021-04-29 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| US-20080207657-A1 | Use Of Minoxidil Sulfate As An Anti-Tumor Drug | CEDARS-SINAI MEDICAL CENTER (US) | 2008-08-28 | — | — | US | claimed |
| US-20040229920-A1 | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use | GARVEY DAVID S (US) | 2004-11-18 | — | — | US | claimed |
| WO-2004056181-A1 | ORGAN PRECONDITIONING, ARREST, PROTECTION, PRESERVATION AND RECOVERY (2) | GLOBAL CARDIAC SOLUTIONS PTY LTD (AU) | 2004-07-08 | — | — | WO | claimed |
| WO-2004056180-A1 | ORGAN PRECONDITIONING, ARREST, PROTECTION, PRESERVATION AND RECOVERY (1) | GLOBAL CARDIAC SOLUTIONS PTY LTD (AU) | 2004-07-08 | — | — | WO | claimed |
| US-20020143188-A1 | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use | GARVEY DAVID S (US) | 2002-10-03 | — | — | US | claimed |
| US-6153627-A | Chroman derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-11-28 | — | — | US | claimed |
| WO-2000067754-A1 | NITROSATED AND NITROSYLATED POTASSIUM CHANNEL ACTIVATORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-11-16 | — | — | WO | claimed |
| US-5284838-A | Hypotensive agents | ELF SANOFI (FR) | 1994-02-08 | — | — | US | claimed |
| EP-0383316-B1 | Process for the separation of enantiomers of benzopyran derivative | MERCK PATENT GMBH (DE) | 1994-02-02 | — | — | EP | claimed |
| EP-0373204-A1 | NOVEL COMPOUNDS AND TREATMENT | BEECHAM GROUP PLC (GB) | 1990-06-20 | — | — | EP | claimed |
| WO-1989010925-A1 | NOVEL COMPOUNDS AND TREATMENT | BEECHAM GROUP PLC (GB) | 1989-11-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | PYGB, PC, KCNN3 | ABCC9 384/4885ABCC8 415/4885KCNJ11 18/4885 |
| US-20260076961-A1 | COMBINATION TREATMENTS | SCNN1B, SCN2B, SCNN1A | ABCC9 255/4885ABCC8 314/4885KCNJ11 97/4885 |
| US-20020143188-A1 | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use | KCNN3, KCNN1, KCNN2 | ABCC9 1769/4885ABCC8 2276/4885KCNJ11 37/4885 |
| US-20040229920-A1 | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use | KCNN3, KCNN1, KCNN2 | ABCC9 1769/4885ABCC8 2276/4885KCNJ11 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.